%PDF-1.4
%
84 0 obj
<>
endobj
157 0 obj
<>/Font<>>>/Fields[]>>
endobj
81 0 obj
<>
endobj
40 1 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2003-11-07T15:47:15Z
2024-03-28T05:18:41-07:00
QuarkXPressª 4.11: AdobePS 8.8.0 (301)
2024-03-28T05:18:41-07:00
application/pdf
Heather
2002-1048.dec
uuid:07501805-1dd2-11b2-0a00-710927edca00
uuid:07501807-1dd2-11b2-0a00-380000000000
endstream
endobj
70 0 obj
<>
endobj
71 0 obj
<>
endobj
85 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 46 0 R/Type/Page>>
endobj
1 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 48 0 R/Type/Page>>
endobj
4 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 50 0 R/Type/Page>>
endobj
7 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 52 0 R/Type/Page>>
endobj
15 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 54 0 R/Type/Page>>
endobj
18 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 56 0 R/Type/Page>>
endobj
21 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 58 0 R/Type/Page>>
endobj
29 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 60 0 R/Type/Page>>
endobj
37 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 62 0 R/Type/Page>>
endobj
196 0 obj
[200 0 R]
endobj
197 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.03 612 -792 re
W n
BT
0 0 0 1 k
/GS1 gs
/T1_0 1 Tf
-0.00011 Tc 0.1749 Tw 10 0 0 10 54 713.1616 Tm
[(adequately control disease activity)64.8 (, clinicians are increas-)]TJ
0.0751 Tw 0 -1.2 TD
(ingly prescribing multiple DMARD in combination)Tj
0 Tc 0 Tw 6.5 0 0 6.5 264.1064 704.4616 Tm
(1,2)Tj
-0.00011 Tc 0.0751 Tw 10 0 0 10 272.2313 701.1616 Tm
(. In a)Tj
0.15199 Tw -21.8231 -1.2 Td
(recent survey of US rheumatologists, 97% reported using)Tj
0.3685 Tw T*
[(combination DMARD therapy)64.8 (, 47% reported that they)]TJ
0.0085 Tc 0.36639 Tw T*
[(consider it appropriate as first-line therapy)64.9 (, and 46%)]TJ
-0.00011 Tc 0.2899 Tw T*
(reported that they prescribe it in at least 30% of their)Tj
0 Tw T*
(patients)Tj
0 Tc 6.5 0 0 6.5 85.1011 644.4615 Tm
(14)Tj
-0.00011 Tc 0.1568 Tw 10 0 0 10 91.601 641.1616 Tm
(. Results from randomized clinical trials support)Tj
0.32249 Tw -3.7601 -1.2 Td
(the very early use of combination traditional DMARD)Tj
0 Tw T*
(therapy)Tj
0 Tc 6.5 0 0 6.5 83.9829 620.4615 Tm
(15,16)Tj
-0.00011 Tc 0.039 Tw 10 0 0 10 98.6078 617.1616 Tm
[(. )17.7 (The advent of biologic DMARD that block the)]TJ
0.01131 Tc 0.3636 Tw -4.4608 -1.2 Td
[(ef)17.6 (fects of )17.7 (TNF-)]TJ
/T1_1 1 Tf
0 Tc 0 Tw 7.0823 0 Td
(\002)Tj
/T1_0 1 Tf
0.01151 Tc 0.3634 Tw 1.2674 0 Td
(has expanded possible combination)Tj
-0.00011 Tc -0.007 Tw -8.3497 -1.2 Td
[(therapy options for RA, although currently available )17.7 (TNF-)]TJ
/T1_1 1 Tf
0 Tc 0 Tw 23.3691 0 Td
(\002)Tj
/T1_0 1 Tf
-0.00011 Tc 0.3531 Tw -23.3691 -1.2 Td
(antagonists have been systematically evaluated only in)Tj
0.0199 Tc 0.5744 Tw T*
(combination with MTX, and not other traditional)Tj
-0.00011 Tc 0 Tw T*
(DMARD)Tj
6.5 0 0 6.5 91.2168 560.4615 Tm
(17-20)Tj
0.1747 Tw 10 0 0 10 106.3796 557.1616 Tm
[(. )54.9 (Anakinra, an interleukin 1 receptor antago-)]TJ
0.09241 Tw -5.238 -1.2 Td
(nist, has been evaluated with concomitant DMARD, corti-)Tj
0.20461 Tw T*
(costeroids, and/or NSAID in a similar safety trial)Tj
0 Tc 0 Tw 6.5 0 0 6.5 264.9075 536.4616 Tm
(21)Tj
-0.00011 Tc 0.20461 Tw 10 0 0 10 271.4074 533.1616 Tm
(. Our)Tj
-0.01579 Tw -21.7407 -1.2 Td
(study is the first randomized clinical trial to examine the use)Tj
T*
[(of a )17.7 (TNF-)]TJ
/T1_1 1 Tf
0 Tc 0 Tw [0.2 (\002)]TJ
/T1_0 1 Tf
-0.00011 Tc -0.01579 Tw 4.8136 0 Td
(antagonist with a variety of currently used tradi-)Tj
0.02499 Tw -4.8136 -1.2 Td
(tional DMARD.)Tj
0.1564 Tw 1.2 -1.21 Td
(This investigation provides key data on the safety and)Tj
0.1042 Tw -1.2 -1.21 Td
[(ef)17.7 (ficacy of adalimumab, the first fully human anti\320TNF-)]TJ
/T1_1 1 Tf
0 Tc 0 Tw [-0.3 (\002)]TJ
/T1_0 1 Tf
-0.00011 Tc 0.10899 Tw 0 -1.21 TD
(mAb to be studied in RA, when given to a heterogeneous)Tj
0.2157 Tw T*
[(group of patients with RA)-410.9 (in combination with multiple)]TJ
0.1367 Tw T*
[(other RA)-331.8 (therapies, as frequently is encountered in actual)]TJ
0.1293 Tw T*
[(clinical practice. )54.8 (Addition of adalimumab 40 mg given sc)]TJ
-0.0262 Tw T*
(every other week to standard antirheumatic therapy was safe)Tj
0.3385 Tw T*
(and well tolerated and provided significant, rapid, and)Tj
0.27831 Tw T*
(sustained improvements in signs and symptoms of RA.)Tj
0.032 Tw T*
(Prior to the availability of biologic DMARD, these patients)Tj
0.0199 Tc 0.4063 Tw T*
(would have been considered responders to standard)Tj
-0.00011 Tc 0.1916 Tw T*
(antirheumatic therapy despite having very active disease.)Tj
0.0063 Tw T*
(The results of this study suggest that what was once consid-)Tj
-0.03281 Tw T*
(ered to be a good response to standard antirheumatic therapy)Tj
0.1228 Tw T*
[(has become inadequate. )54.8 (Adalimumab appears to be a safe)]TJ
0.0313 Tw T*
[(and ef)17.7 (fective therapeutic option for patients with active RA)]TJ
0.0293 Tw T*
(who have an inadequate response to standard antirheumatic)Tj
0.1017 Tw T*
[(therapy)64.8 (, including one or more traditional DMARD, corti-)]TJ
0.02499 Tw T*
(costeroids, NSAID, and analgesics.)Tj
/T1_2 1 Tf
0 Tw 0 -2.4 TD
(ACKNOWLEDGMENT)Tj
/T1_0 1 Tf
0.07919 Tw 8 0 0 8 54 233.2617 Tm
(The authors thank all of the patients who participated and completed thi\
s)Tj
0.0238 Tw 0 -1.25 TD
[(study in the setting of their severe RA. )17.8 (The authors also thank the 69 prin-)]TJ
0.02499 Tw T*
(cipal investigators and their study coordinators.)Tj
/T1_2 1 Tf
0 Tw 10 0 0 10 54 189.2618 Tm
(REFERENCES)Tj
/T1_0 1 Tf
0.02499 Tw 8 0 0 8 61 179.2617 Tm
[(1.)-875.1 (American College of Rheumatology Subcommittee on Rheumatoid)]TJ
1.675 -1.25 Td
(Arthritis Guidelines. Guidelines for the management of rheumatoid)Tj
T*
[(arthritis: 2002 update. )54.8 (Arthritis Rheum 2002;46:328-46.)]TJ
-1.675 -1.25 Td
[(2.)-875.1 (Kremer JM. Rational use of new and existing disease-modifying)]TJ
1.675 -1.25 Td
[(agents in rheumatoid arthritis. )54.8 (Ann Intern Med 2001;138:695-706.)]TJ
-1.675 -1.25 Td
[(3.)-875.1 (Choy EH, Panayi GS. Cytokine pathways and joint inflammation in)]TJ
1.675 -1.25 Td
(rheumatoid arthritis. N Engl J Med 2001;344:907-16.)Tj
-1.675 -1.25 Td
[(4.)-875.1 (Salfeld J, Kaymak\215alan Z, )17.7 (T)35 (racey D, Roberts )54.8 (A, Kamen R.)]TJ
1.675 -1.25 Td
(Generation of fully human anti-TNF antibody D2E7 [abstract].)Tj
T*
(Arthritis Rheum 1998;41 Suppl:S57.)Tj
-1.675 -1.25 Td
[(5.)-875.1 (Barrera P)110.7 (, Joosten LA, den Broeder )54.7 (AA, van de Putte LB, van Riel)]TJ
34.675 79.4084 Td
[(PL, van den Ber)17.7 (g )17.7 (WB. Ef)17.7 (fects of treatment with a fully human)]TJ
T*
(anti-tumour necrosis factor alpha monoclonal antibody on the local)Tj
T*
[(and systemic homeostasis of interleukin 1 and )17.7 (TNF alpha in)]TJ
T*
[(patients with rheumatoid arthritis. )54.8 (Ann Rheum Dis 2001;60:660-9.)]TJ
-1.675 -1.25 Td
[(6.)-875.1 (den Broeder )54.8 (AA, Joosten LA, Saxne )17.7 (T)74 (, et al. Long term anti-tumour)]TJ
1.675 -1.25 Td
[(necrosis factor alpha monotherapy in rheumatoid arthritis: ef)17.7 (fect on)]TJ
T*
(radiological course and prognostic value of markers of cartilage)Tj
T*
[(turnover and endothelial activation. )54.8 (Ann Rheum Dis 2002;61:31)36.8 (1-8.)]TJ
-1.675 -1.25 Td
[(7.)-875.1 (Barrera P)110.7 (, van der Maas )54.7 (A, van Ede )54.7 (AE, et al. Drug survival, )]TJ
1.675 -1.25 Td
[(ef)17.7 (ficacy and toxicity of monotherapy with a fully human )]TJ
T*
[(anti-tumour necrosis factor)19.7 (-alpha antibody compared with)]TJ
T*
(methotrexate in long-standing rheumatoid arthritis. Rheumatology)Tj
T*
(Oxford 2002;41:430-9.)Tj
-1.675 -1.25 Td
[(8.)-875.1 (Den Broeder )54.8 (A, van de Putte L, Rau R, et al. )54.8 (A)-220.1 (single dose, placebo)]TJ
1.675 -1.25 Td
[(controlled study of the fully human anti-tumor necrosis factor)19.7 (-alpha)]TJ
T*
(antibody adalimumab \(D2E7\) in patients with rheumatoid arthritis.)Tj
T*
(J Rheumatol 2002;29:2288-98.)Tj
-1.675 -1.25 Td
[(9.)-875.1 (Arnett FC, Edworthy SM, Bloch DA, et al. )17.7 (The )54.8 (American)]TJ
1.675 -1.25 Td
[(Rheumatism )54.8 (Association 1987 revised criteria for the classification)]TJ
T*
[(of rheumatoid arthritis. )54.8 (Arthritis Rheum 1988;31:315-24.)]TJ
-2.175 -1.25 Td
[(10.)-875.1 (Felson DT)73.9 (, )54.8 (Anderson JJ, Boers M, et al. )17.7 (The )54.8 (American College of)]TJ
2.175 -1.25 Td
(Rheumatology preliminary core set of disease activity measures for)Tj
T*
[(rheumatoid arthritis clinical trials. )17.7 (The Committee on Outcome)]TJ
T*
[(Measures in Rheumatoid )54.8 (Arthritis Clinical )17.7 (T)35 (rials. )54.8 (Arthritis Rheum)]TJ
0 Tc 0 Tw T*
(1993;36:729-40.)Tj
-0.00011 Tc 0.02499 Tw -2.1381 -1.25 Td
[(1)36.8 (1)-0.1 (.)-875.1 (Singh G, Ramey DR, Rausch PL, Schettler JD. Serious infections)]TJ
2.1381 -1.25 Td
(in rheumatoid arthritis: relationship to immunosuppressive use)Tj
T*
[([abstract]. )54.8 (Arthritis Rheum 1999;42 Suppl:S242.)]TJ
-2.175 -1.25 Td
[(12.)-875.1 (Doran MF)79.7 (, Crowson CS, Pond GR, O\325Fallon )17.7 (WM, Gabriel SE.)]TJ
2.175 -1.25 Td
(Frequency of infection in patients with rheumatoid arthritis)Tj
T*
[(compared with controls: a population-based study)64.8 (. )54.8 (Arthritis Rheum)]TJ
0 Tc 0 Tw T*
(2002;46:2287-93.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(13.)-875.1 (Park )36.8 (YB, Choi HK, Kim MY)128.8 (, et al. Ef)17.7 (fects of antirheumatic therapy)]TJ
2.175 -1.25 Td
(on serum lipid levels in patients with rheumatoid arthritis: a)Tj
T*
[(prospective study)64.9 (. )54.8 (Am J Med 2002;1)36.8 (13:188-93.)]TJ
-2.175 -1.25 Td
[(14.)-875.1 (Mikuls )17.7 (TR, O\325Dell J. )17.7 (The changing face of rheumatoid arthritis)]TJ
2.175 -1.25 Td
[(therapy: results of serial surveys. )54.8 (Arthritis Rheum 2000;43:464-5.)]TJ
-2.175 -1.25 Td
[(15.)-875.1 (Boers M, )17.7 (V)110.8 (erhoeven )54.8 (AC, Markusse HM, et al. Randomised)]TJ
2.175 -1.25 Td
(comparison of combined step-down prednisolone, methotrexate and)Tj
T*
(sulphasalazine with sulphasalazine alone in early rheumatoid)Tj
T*
(arthritis. Lancet 1997;350:309-18.)Tj
-2.175 -1.25 Td
[(16.)-875.1 (Mottonen )17.7 (T)74 (,)-0.1 ( Hannonen P)110.7 (, Leirisalo-Repo M, et al. Comparison of)]TJ
2.175 -1.25 Td
(combination therapy with single-drug therapy in early rheumatoid)Tj
T*
(arthritis: a randomised trial. Lancet 1999;353:1568-73.)Tj
-2.175 -1.25 Td
[(17.)-875.1 (W)79.9 (einblatt ME, Kremer JM, Bankhurst )54.8 (AD, et al. )54.8 (A)-220.1 (trial of )]TJ
2.175 -1.25 Td
(etanercept, a recombinant tumor necrosis factor receptor:Fc fusion)Tj
T*
(protein, in patients with rheumatoid arthritis receiving)Tj
T*
(methotrexate. N Engl J Med 1999;340:253-9.)Tj
-2.175 -1.25 Td
[(18.)-875.1 (Maini R, St. Clair EW)91.7 (, Breedveld F)79.7 (, et al. Infliximab \(chimeric)]TJ
2.175 -1.25 Td
(anti-tumour necrosis factor alpha monoclonal antibody\) versus)Tj
T*
(placebo in rheumatoid arthritis patients receiving concomitant)Tj
T*
(methotrexate: a randomised phase III trial. Lancet )Tj
0 Tc 0 Tw T*
(1999;354:1932-9.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(19.)-875.1 (Lipsky PE, van der Heijde DM, St. Clair EW)91.7 (, et al. Infliximab and)]TJ
2.175 -1.25 Td
(methotrexate in the treatment of rheumatoid arthritis. N Engl J Med)Tj
0 Tc 0 Tw T*
(2000;343:1594-602.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(20.)-875.1 (Kavanaugh )54.8 (A, St. Clair EW)91.7 (, McCune )17.7 (WJ, Braakman )17.7 (T)74 (, Lipsky P)110.7 (.)]TJ
2.175 -1.25 Td
[(Chimeric anti-tumor necrosis factor)19.7 (-alpha monoclonal antibody)]TJ
T*
(treatment of patients with rheumatoid arthritis receiving)Tj
T*
[(methotrexate therapy)64.8 (. J Rheumatol 2000;27:841-50.)]TJ
-2.175 -1.25 Td
[(21.)-875.1 (Fleischmann RM, Schechtman J, Bennett R, et al. )54.8 (Anakinra, a)]TJ
2.175 -1.25 Td
(recombinant human interleukin-1 receptor antagonist )Tj
T*
[(\(r)19.7 (-metHuIL-1ra\), in patients with rheumatoid arthritis. )54.8 (Arthritis)]TJ
0 Tc T*
(Rheum 2003;48:927-34.)Tj
ET
0 0 0 1 K
54 54 m
558 54 l
S
BT
/T1_3 1 Tf
-0.00011 Tc 8 0 0 8 54.5 35.9844 Tm
(Furst, et al: Safety trial of adalimumab)Tj
0 Tc 0 Tw 60.9375 -0.0313 Td
(2571)Tj
ET
0 0 0 0 k
/GS0 gs
109.22 59.09 396.48 -10.84 re
f*
0.5 w
109.22 59.09 396.48 -10.84 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 0 0 rg
/GS2 gs
/T1_4 8 Tf
117.48 51 Td
(Personal, non-commercial use only. The Journal of Rheumatology Copyrig\
ht \251 2003. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_5 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 28, 2024 from )Tj
ET
endstream
endobj
62 0 obj
<>stream
8;Z\7Mf&VO#ikr7OPcILG8QN/?FincZrBu92C5ddOK/;`s7NFY%+hi)rgl'Pa7J8%
/>_Oqjn!jgh8]Hm*Dtb*_(FWo%[RNb]^bLS0pZi&V3`hg^ed.2V7NEoeKY<_gF4ML
C]nL)+j^rm/.eBc())iA(ugsA?fF]K1g?po67d+kDZ5O=o__30aAsIuh]Hou2'b_)
`=^(Ol,DM"RdXH@_3Kq^&"U,8<_<[%MF;J=IBM6AGVh[(Obm.lqTWLC$>9IG)tDCFX1>Q
MOt60p2(7:Ric=q''j.":V%IPYHEPK"rQREnQ%WB3]uc649(JkCiJIh-PBq)._8^I
MNq:qgR#`B8UYD,j%=!'`tEAY8;!_EFq)+KD;+*//TOfl^Eu$u1D].a!K6MC56Vg1
<7kV/.Oo/'\r'3P=7OO;C!A$[7LErQBi_L\k9]J$V2p&OB%i`["9V8=,GM
pFuG8IieP^l]0U3_O?HkF\]g?*B?jQ93Khba7Q'RL[M*ETflalEs%;Qr0f'tA:fAX
aO#2-Xcqg=7mI"IoIs-U`2F?&qp"XZM\C^LKf5&EDSK?Mk>O<\]V]:8#DrUE4ZP8C
B.Tr;lCT#ZN(8nM<*"J32880g710q!6u=](j)_!C#"f8);aI_V::t#c^Kuu+m'n,:
`01)l8ruW_\(GCSAac9VQ005o?NU9_XSHr~>
endstream
endobj
68 0 obj
[/Indexed/DeviceRGB 255 67 0 R]
endobj
67 0 obj
<>stream
J,g]g+e/h_!_gCtO=0f)$P%cIi8Zdfc5&3j_8$7g.@L`YKUJNGBP\poR=_;Dl'P(T
(7Boo^^S:71(MN]ZQX/+Cbu.lK"p74pe1T%s.DY%&\1TdJhr54.M9au6>79n6`Q:4
PbLSZTLEE(8E@'*1mg_*eTnN*;*'V3+gm-EEetX%;Bo$ur2ss*N`.-!.kG_q6GDD'
dKoL!8Ka#EV,@V!\j8ZFbp6EE<9cn=N6j0nf;(&;QU6bUD')c@\
9-d\DA=cZ0Q>gIM$$;cd2O@&a;X,Nn_aP(]I1aRc(K1^ue>
gF/(+GaKo$qneLWDrQ#;5\S(\$q'4Q,85`-8;S(=Z"WSBOV*FM)4,?B],R
endstream
endobj
89 0 obj
<>
endobj
93 0 obj
<>
endobj
43 0 obj
<>
endobj
90 0 obj
<>
endobj
113 0 obj
<>
endobj
165 0 obj
<>
endobj
87 0 obj
<>
endobj
108 0 obj
<>stream
HUkPgGOQ.AZPQX/
墈AR\ $@((( 0PQhWTʮ]uv]fҗNygy9s3sc8:00sݺkW-K#ɲR~fǠ=1zŤ;zMqr}Gڛ3m@?~f^د%%!
-&gaDE}?>~~[Dr01IJ}rkV}>ZjS(^@%RAڑvD$NRAEmJI>p%X 3:OIA*_Li"<]@mF|EbJ8͓%!_,HMg`Ӈf0f;0f1>Xbl&\1qccn?րppb`::8x8ƪgV3f<:hY~ܞjv7w=jβ9Ns4Χ\<\*q}HF"eVG3o? ťZ0YFioI`]rw
G~wݾo'1eաUR q9v}SޖJuhiа\+uQ6Y{kk睺vw¡\t8.+g\Vel(!ꔥ)
B|>
{.>GXꁍ#{șpFc݅1Z*Hcc*(P,<"AH2X\*o{4|IfYfd27fa({)th^ZTָM}z[mWc/SzjіEա
հ"ډ2Cd*mLاHx^[a [bdag1i/YXp%l+7̺oDMi}ʤ/CxrhcK:n|K7;W/W/J2"~"sS `>cB0YSwh$ROQ%H?˕dJ̹#yIrxVZ*pvl%j_?x]7f}9he=_M.,֞_,e>
T DgDAc_o>, `ELHƂ;z#fvY@J1"}
ٶEXE2F)H33;jr 9ozY,n< f 5{^_NkcqCX+ZW&&(+ kPR!/M,Cq>>G3h#dâ#$F/Ljo|g)kB^0xr֣&-T{!
YS7,+=sΕw{GgD}|nw%Re՛NoD)·G.In"ݳ{w&ޒMO \z.5v]O#\MPbm %6֖[|ʔlpiF%TXXԾznV}+q_Fpm3Oɗz ܀:XV<5;Tm}ܚc2mۗmhZyFm OwA~BQtTnrAzX'w\I$&ID'apoKp%^-64waE̠+0' haüƴϦIMR,6MZUъl䀸1h&qyK
Uʊݲ)LRw[sae9! 'hoG>VHoupŞˈ !?A
4HّP@VZȂ!M#)D^r(Z+/f GCbwZviql.Ml$cҥZmrQvq>ǔoL;4Bp0Ii7F;٘ݟrK[Ѣj-RsOr-Y'.ioh!y jjDk
m0S,ʪX](A\ $g$